To prevent surgery-related shortcomings, several non-surgical (e.g. mechanical) and enzymatic debriding means are still used but all are inefficiently slow and may involve eschar and wound-handling complications.
Debride
NexoBrid™ significantly reduces time to successful eschar removal allowing treatment to progress to the next stage of wound closure more rapidly.
Protect
The efficacy of NexoBrid™ at removing eschar is achieved without the “collateral damage” of harming the surrounding viable tissues, mainly the dermis.
MediWound’s flagship innovative drug, NexoBrid™, is indicated for the removal of eschar in adults with deep partial- and full-thickness thermal burns, a process also known as debridement. > Read More
The use of this website is subject to the following Terms of Use: The information provided by this website is provided “as is”. Any use of such information by the reader shall be the sole liability of the reader who shall have no claim against MediWound Ltd and/or the website operators, regarding such use.
This website is designated solely for the use of physicians / pharmacists / nurses qualified to work in their professions in their country.